L007
Pill imprint L007 has been identified as Divalproex sodium delayed-release 500 mg.
Divalproex sodium is used in the treatment of bipolar disorder; migraine prevention; mania; epilepsy; hyperekplexia and belongs to the drug class fatty acid derivative anticonvulsants. There is positive evidence of human fetal risk during pregnancy.
Divalproex sodium 500 mg is not subject to the Controlled Substances Act.
See also related documents.
Divalproex sodium delayed-release Images
- Imprint:
-
L007
- Strength:
- 500 mg
- Color:
- Purple
- Shape:
- Elliptical / Oval
- Availability:
- Prescription only
- Drug Class:
- Fatty acid derivative anticonvulsants
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Lupin Pharmaceuticals, Inc
- National Drug Code (NDC):
- 68180-0267
| NDC Code | Manufacturer / Repackager |
|---|---|
| 68084-0315 | Amerisource Health Services |
| 54868-6072 | Physicians Total Care Inc (repackager) |
| 16590-0648 | Stat RX USA LLC (repackager) |
Note: Inactive ingredients may vary.
Advertisement
More Divalproex Sodium Delayed-Release resources
- Divalproex Delayed-Release Tablets (Wolters Kluwer)
- Divalproex Extended-Release Tablets (Wolters Kluwer)
- Divalproex Sprinkle Capsules (Wolters Kluwer)
- divalproex sodium (Cerner Multum)
- Alti-Valproic (Micromedex) - Includes Dosage Information
- Depakote DR (Micromedex) - Includes Dosage Information
- divalproex sodium (Micromedex) - Includes Dosage Information
- Depakote Pellets (FDA)
- Divalproex (FDA)
- Divalproex Capsules (FDA)
- Divalproex Delayed Release (FDA)
- Divalproex Extended Release (FDA)
- Divalproex Sprinkle (FDA)
Search Again
